Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock

Novavax (NVAX) has outperformed recently with a 14% gain over the past month and consistently beat revenue and EPS estimates in the last four quarters. However, analyst consensus presents a mixed forward outlook, projecting a significant +317.9% EPS growth and +51.5% revenue increase for the current fiscal year, yet a sharp -96% EPS decline and -53% revenue drop for the next fiscal year, with substantial negative revisions in recent weeks. Despite a Zacks Value Style Score of 'B' indicating a discount to peers, the stock holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market.

Analysis

Novavax (NVAX) has demonstrated significant recent stock price momentum, returning +14% over the past month, substantially outperforming both the S&P 500 composite's +2.7% gain and its own Medical - Biomedical and Genetics industry's -1% loss. This performance is supported by a strong history of beating analyst expectations, having surpassed consensus revenue and EPS estimates in each of the last four quarters. In its most recent report, the company posted a revenue surprise of +102.74% and an EPS surprise of +985.71%. However, the forward-looking consensus estimates present a sharply contrasting and mixed picture. While the current fiscal year is projected to see substantial growth with EPS increasing +317.9% and revenue rising +51.5%, the outlook for the next fiscal year indicates a severe contraction. Analyst consensus for the next fiscal year projects an EPS decline of -96% and a revenue drop of -53%, with the EPS estimate having been revised downward by a significant -60.3% over the last 30 days. This negative revision trend, coupled with an expected current quarter revenue decline of -20.7%, aligns with the Zacks Rank #3 (Hold) rating, suggesting the stock may perform in line with the broader market despite its 'B' grade for value, which indicates it is trading at a discount to its peers.

Key Decisions for Investors

• Given the stark contrast between strong current-year forecasts and the projected sharp decline in the next fiscal year, investors should be cautious of the significant forward-looking risk, as reflected in the recent -60.3% downward revision of next year's EPS estimate.
• While the stock's 'B' value grade suggests a potential discount, this may be warranted by the expected -53% revenue contraction next year; therefore, valuation should be weighed heavily against the deteriorating long-term growth outlook.
• The stock's history of large earnings surprises and recent +14% momentum may offer opportunities for short-term, catalyst-driven trades, but the Zacks #3 (Hold) rating and negative forward revisions signal caution for long-term, buy-and-hold positions.
• Monitor upcoming earnings reports not just for beats against consensus but for any revisions to future guidance, as any mitigation of the projected 2025 earnings and revenue cliff will be a critical determinant of the stock's future trajectory.